Investigations in the 99mTc chemistry are stimulated by the search for new radiopharmaceuticals for nuclear medical applications. To understand the coordination mode of Tc with various complexing agents, macroscopic studies of technetium coordination chemistry are often performed using the low energy ß-emitting radionuclide 99Tc, which has a much longer half life (t1/2 = 2.12 x 105 years) than 99mTc, in the mg level. Investigations of Re coordination chemistry are done in conjunction with Tc studies because Re possesses chemical properties similar to those of Tc. For some chemical tasks, Re provides a non-radioactive alternative to work with Tc radioisotopes. In addition, 186Re and 188Re are of great interest to nuclear medicine as they pos...
The research was based on the observation that despite the extraordinarily rich coordination chemist...
A novel procedure for the high-yield preparation of Re-188 radiopharmaceuticals containing a termina...
In 2021, it is projected that 1 in 2 men and 1 in 3 women will receive a new cancer diagnosis, resul...
Investigations in the 99mTc chemistry are stimulated by the search for new radiopharmaceuticals for ...
Investigations in the 99mTc chemistry are stimulated by the search for new radiopharmaceuticals for ...
Due to its long half-life of 2.111×105 y, technetium, i.e. 99Tc, offers the excellent opportunity of...
A number of rhenium compounds were synthesized and characterized in an attempt to investigate and ex...
Medical Department, Brookhaven National Laboratory, Upton, New York 11973, U.S.A. Significant adva...
Due to its long half-life of 2.111×105 y, technetium, i.e. 99Tc, offers the excellent opportunity of...
A number of rhenium compounds were synthesized and characterized in attempts to investigate and expa...
This study focuses on the design, development, and synthesis of technetium and rhenium radiopharmace...
Technetium-99m is the major isotope used in diagnostic radiopharmaceuticals, and it will continue t...
Technetium-99m is the major isotope used in diagnostic radiopharmaceuticals, and it will continue t...
The β− emitter, rhenium-188 (188Re), has long been recognized as an attractive candidate for targete...
Abstract from public.pdf file.Dissertation supervisors: Drs. Silvia Jurisson and Heather Hennkens.In...
The research was based on the observation that despite the extraordinarily rich coordination chemist...
A novel procedure for the high-yield preparation of Re-188 radiopharmaceuticals containing a termina...
In 2021, it is projected that 1 in 2 men and 1 in 3 women will receive a new cancer diagnosis, resul...
Investigations in the 99mTc chemistry are stimulated by the search for new radiopharmaceuticals for ...
Investigations in the 99mTc chemistry are stimulated by the search for new radiopharmaceuticals for ...
Due to its long half-life of 2.111×105 y, technetium, i.e. 99Tc, offers the excellent opportunity of...
A number of rhenium compounds were synthesized and characterized in an attempt to investigate and ex...
Medical Department, Brookhaven National Laboratory, Upton, New York 11973, U.S.A. Significant adva...
Due to its long half-life of 2.111×105 y, technetium, i.e. 99Tc, offers the excellent opportunity of...
A number of rhenium compounds were synthesized and characterized in attempts to investigate and expa...
This study focuses on the design, development, and synthesis of technetium and rhenium radiopharmace...
Technetium-99m is the major isotope used in diagnostic radiopharmaceuticals, and it will continue t...
Technetium-99m is the major isotope used in diagnostic radiopharmaceuticals, and it will continue t...
The β− emitter, rhenium-188 (188Re), has long been recognized as an attractive candidate for targete...
Abstract from public.pdf file.Dissertation supervisors: Drs. Silvia Jurisson and Heather Hennkens.In...
The research was based on the observation that despite the extraordinarily rich coordination chemist...
A novel procedure for the high-yield preparation of Re-188 radiopharmaceuticals containing a termina...
In 2021, it is projected that 1 in 2 men and 1 in 3 women will receive a new cancer diagnosis, resul...